Docking and molecular dynamic simulations of Mithramycin-A and Tolfenamic acid against Sp1 and survivin
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Mithramycin-A shows superior binding to Sp1 and survivin compared to Tolfenamic acid, suggesting its potential as an effective cancer therapeutic by targeting these overexpressed proteins.
Area Of Science
- Oncology
- Molecular Biology
- Drug Discovery
Background
- Sp1 transcription factor and survivin are overexpressed in many cancers, correlating with poor prognosis.
- Downregulating these markers is a potential cancer treatment strategy.
- Mithramycin-A and Tolfenamic acid are investigated for their anti-cancer properties and ability to target Sp1.
Purpose Of The Study
- To investigate the binding interactions of Mithramycin-A and Tolfenamic acid with Sp1 and survivin.
- To identify critical residues involved in drug-protein interactions.
- To evaluate Mithramycin-A as a superior therapeutic candidate.
Main Methods
- Molecular docking analysis to predict binding affinities.
- Molecular dynamics simulations (RMSF, RMSD, rGYr, H-bond analysis) to assess stability and interactions.
- Identification of key amino acid residues in drug-protein complexes.
Main Results
- Mithramycin-A demonstrated stronger binding affinity to both Sp1 and survivin compared to Tolfenamic acid.
- Molecular dynamics simulations confirmed Mithramycin-A's superior binding and identified crucial interacting residues.
- The binding trend observed in docking was consistent with simulation results.
Conclusions
- Mithramycin-A is a more effective binding agent for Sp1 and survivin than Tolfenamic acid.
- Further research into Mithramycin-A's interaction with Sp1 and downstream targets is warranted.
- Mithramycin-A shows promise as a potential anti-cancer therapeutic agent.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
